Skip to content

Open-label study on safety and pharmacokinetics of [11C]thiamine in normal subjects

Open-label study on safety and pharmacokinetics of [11C]thiamine in normal subjects - PET pharmacokinetics of [11C]thiamine

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030940
Enrollment
3
Registered
2018-01-23
Start date
2018-01-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal subjects

Interventions

PET imaging for 90min with single intravenous injection of [11C]thiamine (30-400MBq), which takes 4 hours in total including preparation and safety examinations.

Sponsors

Kobe City Medical Center General Hospital, Center for Clinical Research and Innovation
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Informed consent 2.Japanese male of 20y.o. or older and younger than 65y.o. 3.Body weight being 50kg or higher and lower than 85kg. BMI being 18.5 or higher and lower than 26.5 4.Healthy enough for this study

Exclusion criteria

Exclusion criteria: 1)Allergy to drugs and/or foods 2)Serious disease in liver, kidney, heart, blood or vascular system. 3)Medication or dietary supplement within 7 days prior to PET scan. 4)Habitual intake of drugs or dietary supplements containing vitamin B1 or derivatives. Such intake within 1 month prior to PET scan. 5)Habitual heavy alcohol drinker or such intake within 7 days prior to PET scan. 6)Blood donation of 200mL or more within 1 month, 400mL or more within 3months 7)Should avoid further radiation exposure, based on radiation exposure history 8)Syphilis, HIV, Hepatitis B or C infection 9)Drug or alcohol abuse. 10)Inappropriate for a subject of this study for other reasons

Design outcomes

Primary

MeasureTime frame
Safety (ECG, blood count, blood chemistry, urine at 90 min post injection)

Secondary

MeasureTime frame
Radiation exposure dosimetry Whole-body pharmacokinetics for 90min

Countries

Japan

Contacts

Public ContactKiyoshi Irikura

Kobe City Medical Center General Hospital Center for Clinical Research and Innovation

irikura@fbri.org078-304-5212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026